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Krüppel-like factor 6 is a 
transcriptional activator of 
autophagy in acute liver injury
Svenja Sydor1,2, Paul Manka1,3, Jan Best1, Sami Jafoui1, Jan-Peter Sowa1, Miguel Eugenio 
Zoubek4, Virginia Hernandez-Gea5, Francisco Javier Cubero4,6, Julia Kälsch1,7, Diana Vetter8, 
Maria Isabel Fiel9, Yujin Hoshida  9, C. Billie Bian9, Leonard J. Nelson  10, Han Moshage11,12, 
Klaas Nico Faber11,12, Andreas Paul13, Hideo A. Baba7, Guido Gerken1, Scott L. Friedman  9, 
Ali Canbay1,2 & Lars P. Bechmann1,2
Krüppel-like factor 6 (KLF6) is a transcription factor and tumor suppressor. We previously identified 
KLF6 as mediator of hepatocyte glucose and lipid homeostasis. The loss or reduction of KLF6 is linked 
to the progression of hepatocellular carcinoma, but its contribution to liver regeneration and repair 
in acute liver injury are lacking so far. Here we explore the role of KLF6 in acute liver injury models in 
mice, and in patients with acute liver failure (ALF). KLF6 was induced in hepatocytes in ALF, and in 
both acetaminophen (APAP)- and carbon tetrachloride (CCl4)-treated mice. In mice with hepatocyte-
specific Klf6 knockout (DeltaKlf6), cell proliferation following partial hepatectomy (PHx) was increased 
compared to controls. Interestingly, key autophagic markers and mediators LC3-II, Atg7 and Beclin1 
were reduced in DeltaKlf6 mice livers. Using luciferase assay and ChIP, KLF6 was established as a direct 
transcriptional activator of ATG7 and BECLIN1, but was dependent on the presence of p53. Here we 
show, that KLF6 expression is induced in ALF and in the regenerating liver, where it activates autophagy 
by transcriptional induction of ATG7 and BECLIN1 in a p53-dependent manner. These findings couple 
the activity of an important growth inhibitor in liver to the induction of autophagy in hepatocytes.
Krüppel-like factor 6 (KLF6) is a ubiquitously expressed zinc finger transcription factor, which contributes to cell 
proliferation, differentiation, cell death and signal transduction1. Hepatocyte expression of KLF6 regulates hepatic 
fatty acid and glucose metabolism via transcriptional activation of liver glucokinase and posttranscriptional reg-
ulation of the nuclear receptor peroxisome proliferator activated receptor alpha (PPARα)2, 3. KLF6-expression 
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contributes to hepatic insulin resistance and the progression of non-alcoholic fatty liver disease (NAFLD) to 
non-alcoholic steatohepatitis (NASH) and NASH-cirrhosis4. KLF6 also affects peroxisome proliferator activated 
receptor gamma (PPARγ)-signaling in NAFLD3, 5. Besides their metabolic functions, PPARα and PPARγ regu-
late cell proliferation and apoptosis6. Furthermore, KLF6 has been identified as a tumor suppressor gene that is 
inactivated or downregulated in different cancers including prostate, colon and hepatocellular carcinomas7, 8. 
Consistent with its inhibitory effect on cell proliferation, KLF6 transactivates genes controlling cell proliferation, 
including p21, E-Cadherin and pituary tumor-transforming gene 1 (PTTG1)8–14. Despite its clear growth regula-
tory activity in hepatic metabolism and cancer, there are no studies evaluating the role of KLF6 in liver regenera-
tion and hepatocyte proliferation.
Acute liver injury and acute liver failure (ALF) are rare but serious conditions leading to hepatocyte death 
that occur in a previously healthy organ. ALF is characterized by rapid induction of hepatocyte necro-apoptosis, 
leading to jaundice, hepatic encephalopathy and coagulopathy15. The underlying causes of ALF encompass auto-
immune, viral, toxic or vascular diseases, with drug-induced liver injury and acetaminophen (APAP) poisoning 
as the most predominant etiologies in Western population16, 17. Acetaminophen is a widely used analgesic and 
antipyretic drug. Intake of high doses can result in ALF that is characterized by a rapid loss of liver cells and 
hepatic function due to enhanced production of reactive oxygen species (ROS), causing cellular stress and induc-
tion of cell death17–19. Specific treatment (N-acetyl cysteine (NAC)) promotes liver regeneration by compensation 
of hepatic cell loss and induction of proliferation of remaining cells and by the activation and potential differen-
tiation of quiescent progenitor cells20, 21.
Liver regeneration is governed by a delicate interplay of cytokines, chemokines and the activation of prolifer-
ative and anti-apoptotic signaling pathways. Recent studies have identified autophagy, a conserved mechanism 
to recycle cellular components in cell starvation, to play a role in hepatocellular regeneration in APAP-induced 
ALF by reduction of cellular stress22–24. In this study, we aimed to investigate the role of KLF6 in liver regeneration 
following acute hepatocellular injury and ALF, and identified autophagy-related genes to be transcriptionally 
regulated by KLF6.
Results
KLF6 is induced in hepatocytes during acute human liver injury. We compared KLF6-expression 
by immunohistochemistry between liver tissue from patients with ALF and without (morbidly obese patients 
who underwent bariatric surgery without NASH (NAS < 2) or fibrosis; for patients’ demographical data see 
Supplementary Table S1). KLF6-expression was low in non-acute injury livers and localized primarily in the 
cytoplasm of cholangiocytes, with modest staining in the cytosol or nuclei of hepatocytes (Fig. 1A). In contrast, 
significantly higher nuclear KLF6-expression was detected in hepatocytes in liver tissue of ALF patients, while 
the bile duct regions showed low levels of KLF6 (Fig. 1B; for H&E images of patients’ liver tissue, please see 
Supplementary Figure S1, for quantification of nuclear KLF6 in hepatocytes see Supplementary Table S1).
KLF6 attenuates liver regeneration and autophagy after partial hepatectomy in mice. We 
performed 70% partial hepatectomy (PHx) in C57Bl/6-mice as an established model of liver regeneration25. 
Animals were sacrificed 12 h, 24 h and 48 h after PHx and the remnant liver was analyzed. Expression of Klf6 
was significantly upregulated in liver tissue following PHx in wildtype mice (Fig. 2A) and, as observed in human 
ALF, was mostly detected in the nuclei of hepatocytes (Supplementary Figure S2A). Next, PHx was performed 
in mice with a hepatocyte specific Klf6-knockout (DeltaKlf6) compared to controls2, 3. Enhanced hepatocyte 
proliferation was observed in the absence of Klf6, as assessed by PCNA-staining (Fig. 2B for quantification of 
Figure 1. In acute liver failure (ALF) KLF6 expression is induced in hepatocytes. KLF6 protein was visualized 
in liver tissue of ALF patients by immunohistochemistry. Representative tissue sections of patients with drug-
induced ALF (B) or non-acute liver injury patients (A) stained with KLF6 by immunohistochemistry are shown 
(20-fold magnification).
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Figure 2. KLF6 affects liver regeneration and expression levels of autophagy-related genes after partial 
hepatectomy (PHx). Klf6 expression levels were determined by qRT-PCR in mouse liver tissue before (pre-OP) 
and 12 h, 24 h or 48 h after 70% partial hepatectomy (PHx, n = 6/group) (A). Cell proliferation was assessed 
by quantification of PCNA positive cells in liver tissue of wildtype (wt) and DeltaKlf6 mice 72 h after PHx 
(B). Expression-levels of Atg7 (C) and Beclin1 (D) were measured by qRT-PCR in liver tissue of wt and 
DeltaKlf6 mice before and 12 h after PHx. Autophagy was assessed by LC3 Western blotting and quantified by 
densitometry of specific protein bands (E,F) in liver tissue of wt and DeltaKlf6 mice 72 h after PHx. Shown are 
representative Western blot images (E) and densitometric quantification of LC3-II-bands normalized to loading 
control beta-Actin (F); fold change versus control shown as mean ± SEM of n = 6 mice per group; full length 
Western blot images are given in Supplementary information). *Represents p-value < 0.05 and **Indicates 
p-value < 0.01 as assessed by 2-way ANOVA comparing wt mice with DeltaKlf6 animals at the same time point 
after PHx.
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PCNA positive cells and Supplementary Figure S2B for immunohistochemical PCNA images), and by quantify-
ing liver-to-body-weight-ratios (Table 1). In KLF6-over-expressing HepG2 cells, following transient transfection 
with a KLF6-expression vector (pcIneo-KLF6), proliferation appeared attenuated compared to empty control 
vector (pcIneo) transfected control cells as assessed by BrdU cell proliferation assay (Supplementary Figure S2C).
Liver tissue from DeltaKlf6 mice 12 h after PHx was subjected to RNA-microarray analysis (Affymetrix 
GeneChip HT MG-430 PM), which revealed changes in expression of autophagy-related genes compared to 
wt controls (heatmap included in Supplementary Figure S2D). QRT-PCR confirmed significant reductions in 
Atg7 and Beclin1 expression in DeltaKlf6 livers before and 12 h after PHx compared to wt controls (Fig. 2C,D). 
Attenuation of LC3-II-expression after PHx assessed by Western blot was correlated with loss of Klf6 in DeltaKlf6 
mice (Fig. 2E,F). Western blot revealed high levels of LC3-II in livers of wt mice 72 h post PHx, which was signif-
icantly attenuated in the absence of Klf6 in liver tissue of DeltaKlf6 animals.
KLF6 induction parallels induction of autophagy in vivo and in cell culture. To investigate 
Klf6-expression in an established in vivo model of APAP-induced liver injury26 we employed C57Bl/6-mice that 
received an intra-peritoneal injection of APAP (500 mg/kg bodyweight) or saline in controls (H&E images of liver 
tissue from APAP- or vehicle-treated mice are shown in Supplementary Figure S3A). The animals were sacrificed 
8 h after injection and levels of Klf6 gene expression in liver tissue were assessed by qRT-PCR. APAP-injection 
resulted in significant liver damage as indicated by increased serum ALT-, AST- and GLDH- levels 8 h after 
treatment (Table 2). Hepatic Klf6-expression was significantly increased 8 h after APAP-injection (Fig. 3A). 
Comparing vehicle treated C57Bl/6 mice with those receiving APAP injection; LC3-II-levels were significantly 
enhanced in murine liver tissue after APAP-injection (Fig. 3B, Supplementary Figure S3B for Western blot 
image). To evaluate Klf6 expression in another model of acute liver injury, we injected a single dose of CCl4 to 
DeltaKlf6 and wildtype animals.In livers of animals sacrificed 48 h after receiving an acute dose of CCl4, in parallel 
to acute liver damage (see Table 2 for serum parameters of liver injury) Klf6-expression was as well significantly 
upregulated, compared to mice treated with corn oil alone (Fig. 3C). In this model of acute injury LC3-II levels 
were induced after CCl4 injection, (Fig. 3D,E).
To validate the in vivo observations, we quantified KLF6-expression in APAP treated cell culture models. 
Therefore, we treated HepaRG cells, which resemble the metabolic function of human hepatocytes, with different 
concentrations of APAP (5 mM, 10 mM and 20 mM) for 24 h to induce cellular stress and damage. Here, KLF6 
was significantly upregulated after APAP treatment in a dose-dependent fashion (Supplementary Figure S3C). 
Similarly, in HepG2 cells, treatment with APAP for 24 h significantly induced KLF6-levels (Supplementary 
Figure S3D). We then quantified autophagy-induction in APAP-treated HepG2 cells and observed increased 
LC3-II and p62 levels compared to control cells (Supplementary Figure S3E,F,H and I).
KLF6 induces autophagy and binds to promoter regions of BECLIN1 and ATG7. To verify the 
functional interaction between KLF6 and autophagy related targets, we transiently transfected HepG2 cells with 
an empty control vector (pcIneo) or a KLF6-expression vector (pcIneo-KLF6) in order to quantify autophagy 
induction in KLF6-over-expressing cells (Fig. 4). In parallel to KLF6-overexpression (Fig. 4A,B), LC3-II was 
Time post PHx
Wildtype (C57Bl/6) DeltaKlf6
12 h 24 h 72 h 12 h 24 h 72 h
ALT [U/l] 899.0 ± 649.2 315.8 ± 65.9 20.4 ± 4.4 2015.3 ± 357.1 395.0 ± 244.1 14.0 ± 3.6
AST [U/l] 2093.0 ± 513.3 753.0 ± 98.6 94.2 ± 2.04 3321.0 ± 645.6 462.5 ± 98.6 73.0 ± 10.0
Total bilirubin 
[mg/dl] 0.37 ± 0.12 0.45 ± 0.15 0.3 ± 0.0 0.23 ± 0.042 0.3 ± 0.0 0.23 ± 0.07
Liver/bodyweight 
ratio [%] 1.8 ± 0.09 1.75 ± 0.31 2.5 ± 0.19 2.28 ± 0.009** 2.5 ± 0.23** 2.1 ± 0.18
Table 1. Data from 12 h, 24 h or 72 h after partial hepatectomy (PHx) in wildtype or DeltaKlf6 mice. **p < 0.01 
(wt vs. DeltaKlf6 at same time-point).
APAP (500 mg/kg) Vehicle (n = 6) APAP (n = 8)
ALT [U/l] 53.33 ± 3.33 2259 ± 458.2**
AST [U/l] 60.0 ± 7.07 4090 ± 720.1***
GLDH [U/l] 10.67 ± 0.67 215.5 ± 42.62**
Liver/bodyweight-ratio [%] 7.63 ± 0.38 8.06 ± 0.53
CCl4 (2 µl/g) Vehicle (n = 4) CCl4 (n = 5)
wt DeltaKlf6 wt DeltaKlf6
ALT [U/l] 38.3 ± 8.4 49.2 ± 3.4 733.2 ± 105.7** 704 ± 132.6**
AST [U/l] 12.8 ± 0.8 6.0 ± 1.6** 1444 ± 198** 1423 ± 234.5**
Total bilirubin [mg/dl] 0.1 ± 0.0 0.1 ± 0.0 0.26 ± 0.04* 0.25 ± 0.05*
Table 2. Mouse baseline parameters after treatment with APAP (wildtype animals) or acute CCl4 treatment 
(wildtype and DeltaKlf6 animals). *p < 0.05; **p < 0.01; ***p < 0.001 versus vehicle control.
www.nature.com/scientificreports/
5ScIentIfIc RepoRtS | 7: 8119  | DOI:10.1038/s41598-017-08680-w
increased and p62 levels were decreased in these cells (Fig. 4C,D). To assess autophagosome formation, we per-
formed transmission electron microscopy with control vector transfected HepG2 (pcIneo) cells and pcIneo-KLF6 
transfected HepG2 cells. In KLF6 over-expressing HepG2 cells (Fig. 5C), there were more autophagy-positive 
cells compared to pcIneo-transfected HepG2 cells (Fig. 5A; for quantification of autophagy-positive cells see 
Supplementary Table S2). As a control for autophagy induction and autophagosome-formation we treated 
pcIneo-transfected HepG2 cells with 15 µM of rapamycin for 6 h (Fig. 5B). In addition, we performed Autophagy 
Tandem Sensor RFP-GFP-LC3B assay (Fig. 6), which confirmed increased formation of autophagosomes in 
KLF6-over-expressing HepG2 cells (Fig. 6; Supplementary Table S2). LC3-II turnover was assessed by Western 
blot in HepG2 (pcIneo) and KLF6 over-expressing HepG2 cells (pcIneo-KLF6) in the absence or presence 
of the lysosomal inhibitor chloroquine (100 µM for 24 h; Fig. 4C,D). In the absence of the inhibitor, KLF6 
over-expression led to an increase of LC3-II and a decrease of p62 in comparison to pcIneo transfected cells. 
Incubation with the lysosmal inhibitor chloroquine resulted in a clear accumulation of LC3-II and a suppression 
of p62 in both pcIneo and in pcIneo-KLF6 cells. The use of the lysosomal inhibitor chloroquine demonstrated 
that autophagic flux occurs in these cells. However, in this experiment, there were no significant differences 
Figure 3. KLF6 is induced in different experimental models of acute hepatocellular injury. Klf6-expression 
levels were quantified by qRT-PCR in liver tissue of mice that received vehicle or APAP-injection (A; 500 mg/
kg bodyweight after 8 h, n = 6) and in mice that received a single dose of CCl4 (C; 2 µl/g bodyweight, n = 4 
for vehicle control and n = 5 for CCl4 treated animals). Autophagy was assessed by LC3 Western blotting and 
quantified by densitometry of specific protein bands in liver tissue of wildtype mice following APAP-injection 
(B; Western blot images of APAP-treated mice are show in Supplementary Figure S3) or in wildtype and 
deltaKlf6 animals after CCl4 injection (D,E). Shown are representative Western blot images of CCl4 treated 
animals (E; full length Western blot images are given in Supplementary information) and densitometric 
quantification of LC3-II bands normalized to loading control Actin (E); fold change versus control shown as 
mean ± SEM of n = 4–6 mice).
www.nature.com/scientificreports/
6ScIentIfIc RepoRtS | 7: 8119  | DOI:10.1038/s41598-017-08680-w
in LC3-II levels following chloroquine treatment comparing pcIneo and pcIneo-KLF6 transfected HepG2 cells 
(Fig. 4D).
KLF6 belongs to the family of zinc finger proteins that regulate target genes and cellular pathways by binding 
to specific DNA motifs. We identified potential KLF6 binding motifs within the promoter regions of the auto-
phagy related genes ATG7 and BECLIN1, and then confirmed transcriptional activation by luciferase reporter 
assays. To do so, we performed co-transfection with reporter plasmids in KLF6-over-expressing HepG2 cells 
and specific luciferase reporter plasmids carrying the promoter regions of ATG7 or BECLIN1. A background 
control was comprised of a commercially available random control vector containing a non-conserved, non-genic 
and non-repetitive fragment of equal length to the specific sequence upstream of the luciferase gene. As shown 
in Fig. 4E in HepG2 cells over-expressing KLF6, ATG7 promoter activity was significantly higher compared to 
control plasmid transfected cells. Thus, KLF6 transactivates ATG7 and therefore might influence the level of 
autophagy. Next, we performed chromatin immune precipitation assays (ChIP), which confirmed direct bind-
ing of KLF6 to the promoter regions of ATG7 and BECLIN1 (Fig. 4G). Interestingly, despite active binding of 
KLF6 to the BECLIN1 promoter, BECLIN1 luciferase activity was not altered by KLF6-overexpression in HepG2 
cells (Fig. 4E). Predicted binding elements of KLF6 to promoter regions of ATG7 or BECLIN1 were assessed by 
using ChIP-seq data from KLF6-transfected HepG2 cells that were obtained from the NIH Encyclopedia of DNA 
Elements (ENCODE) database. This analysis clearly identified protein-DNA binding sides of KLF6 on regions 
encoding ATG7 and BECLIN1 (Supplementary Figure S2F+G).
Figure 4. KLF6 transcriptionally activates autophagy-related genes in a p53-dependent manner. Transfection 
with the KLF6-expression vector pcIneo-KLF6 induced KLF6 mRNA (A) and protein (B) expression. KLF6-
over-expression induces autophagy in HepG2 cells as assessed by LC3 Western blotting (C) and quantification 
of LC3-II-bands normalized to loading control GAPDH (D; fold change versus control shown as mean ± SEM 
of n = 3 independent cell culture experiments; full length Western blot images are given in Supplementary 
information.). Autophagic flux was assessed by LC3-II and p62 Western blotting in HepG2 and pcIneo-KLF6 
transfected cells in absence (−) or presence ( + ) of 100 µM chloroquine for 24 h ((C) shows representative 
Western blot images, (D) shows fold change versus control, shown as mean ± SEM of n = 3 independent 
experiments). Activation of the ATG7 and BECLIN1 promoter was quantified by luciferase activity in a co-
transfection experiment of pcIneo-KLF6 with specific promoter reporter luciferase plasmids in HepG2 (E) 
and in p53-deficient HepG2-303 cells (F). The interaction of KLF6 with the ATG7 and BECLIN1 promoter 
containing putative KLF6-binding sites was confirmed by chromosomal immunoprecipitation (ChIP) in HepG2 
cells (G) using two different KLF6 antibodies, IgG as negative controls, Histone-H3 antibody was used as a 
positive control for ChIP; full length images of agarose gels are given in Supplementary information.
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The p53-dependant transcriptional activation of ATG7 and BECLIN1 by KLF6 is independent 
of apoptosis. A direct interaction between KLF6 and p53 has previously been demonstrated in the context 
of IGF-1 regulation27, 28. In contrast to KLF6, several direct and indirect interactions between autophagy and 
p53 have identified p53 as an important regulator of autophagy29. To investigate a potential interaction between 
KLF6 and p53 in the context of autophagy-induction, we used p53-deficient HepG2-303 cells to determine 
if KLF6 still leads to upregulation of autophagy-related genes in the absence of p53. To do so, we performed 
luciferase assays in KLF6-over-expressing HepG2-303 cells transfected with promoter-reporter constructs 
for ATG7 and BECLIN1. In contrast to p53-expressing HepG2 cells, the ATG7 promoter was not activated in 
KLF6-over-expressing HepG2-303 cells (Fig. 4F). Interestingly, the activation of BECLIN1 in HepG2-303 cells 
was enhanced in KLF6-over-expressing cells compared to control cells, pointing towards p53-dependent (ATG7) 
and p53-independent (BECLIN1) mechanisms, by which KLF6 regulates autophagy-related effector proteins. 
However, LC3-II-levels were obviously not changed in HepG2-303 cells treated with APAP or in HepG2-303 cells 
over-expressing KLF6 (Supplementary Figure S3G,J), implying that p53 is required to enhance LC3-II as a marker 
for increased autophagosome formation.
To elucidate potential non-transcriptional effects of KLF6 on autophagy-induction, we further investigated 
its role in apoptosis-induction. Following cellular stress, autophagy can block apoptosis or caspase activation and 
promote survival by clearance of reactive oxygen species or damaged proteins. A switch from autophagy to apop-
tosis may occur, since autophagic and apoptotic molecules including BECLIN1 and BCL-2 interact directly30, 31. 
Since p53 is also an activator of apoptosis and several mediators involved in autophagy-induction also contribute 
to Caspase-regulation/apoptosis-regulation, we measured expression levels of the apoptosis-related molecules 
BAX, BAD and BCL-2. Expression of these genes was not changed in KLF6-over-expressing cells compared to 
empty vector transfected HepG2 cells. However, as previously published, expression levels of P21 were reduced 
in KLF6-over-expressing HepG2 cells (Supplementary Table S3). Additionally, we performed a Proteome Profiler 
human Apoptosis Array to analyze the expression profiles of 35 apoptosis-related proteins using cell lysates from 
normal HepG2 cells (pcIneo) and KLF6-over-expressing HepG2 cells. This array did not highlight any differences 
between control vector transfected and KLF6-over-expressing HepG2 cells (Supplementary Figure S2E).
Discussion
KLF6 is a growth suppressor gene and the inactivation of KLF6 is associated with multiple human tumors7, 8, 11. 
Among several mechanisms of tumor suppression, KLF6 inhibits cell cycle progression and proliferation32. 
However, the behavior of KLF6 during liver regeneration following acute liver injury has not been assessed to 
date. With this study we establish that KLF6 is induced and translocated to the nucleus in hepatocytes among 
different models of acute liver injury. This activation is associated with enhanced hepatocyte proliferation in 
early liver regeneration. We further identify KLF6 as a transcriptional activator of ATG7 and BECLIN1, thereby 
Figure 5. Autophagosome formation in KLF6 over-expressing HepG2 cells. Under a transmission electron 
microscope, the autophagosome formation was observed and imaged in HepG2 cells transfected with the empty 
vector (pcIneo) (A), in HepG2 cells transfected with pcIneo treated with 15 µM rapamycin for 6 h to stimulate 
autophagosome formation (B) and in KLF6-over-expressing HepG2 cells (pcIneo-KLF6) (C). Representative 
slides and blow-ups shown are shown of n = 2 independent cell culture experiments.
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establishing KLF6 as a novel mediator of autophagy. This novel function of KLF6 depends on the presence of p53, 
but appears to be independent of apoptosis.
Healthy liver tissue has the ability to compensate for the loss of organ function in case of induced cell stress, 
acute injury or cell death. However, the excessive loss of functional liver tissue may lead to ALF. Following cell 
loss or death, activation of cell proliferation and regeneration, combined with attenuation of growth suppressor 
activity within remnant liver tissue restores liver cell mass. Downregulation of KLF6, a tumor suppressor gene 
that inhibits proliferation through induction of p21 and in synergy with p538, 10, 12 has been observed in primary 
liver tumors and is associated with a worse outcome in cancer1, 11, 33. Following PHx in mice, hepatocyte-specific 
deletion of Klf6 accelerates cell proliferation at early time points after resection. The later loss of growth induc-
tion in DeltaKlf6 mice suggests that mechanisms not related to hepatocellular Klf6 override its anti-proliferative 
effects as hepatocyte regeneration progresses. Furthermore, these observations might as well be confounded by 
Klf6-expression in non-parenchymal cells34, 35. Here, cell proliferation was slightly reduced in in vitro experi-
ments using KLF6-over-expressing HepG2 cells as shown by BrdU assay. Furthermore, KLF6-overexpression 
was accompanied with reduced expression levels of p21 in transiently transfected HepG2 cells. This transcription 
factor regulates cell cycle progression, DNA replication and repair by regulating the activity of different cyclin 
dependent kinases; its activation is controlled by the tumor suppressor protein p5336, 37. Nonetheless, we observed 
a strong hepatocyte induction of KLF6 in models of acute liver injury and ALF patients, and an early proliferative 
advantage for hepatocyte-specific Klf6 knockout mice undergoing PHx.
Figure 6. Autophagosome formation in KLF6 over-expressing HepG2 cells. To visualize formation of 
autophagosomes in HepG2 cells transfected with empty control vector (pcIneo) or in KLF6 over-expressing 
HepG2 cells (pcIneoKLF6) we treated the cells with Autophagy Tandem Sensor RFP-GFP-LC3B. As a positive 
control, we stimulated autophagosome formation via treatment with 15 µM rapamycin for 6 h. Cells were viewed 
and imaged with a Leica SP8 confocal microscope (20-fold magnification); shown are representative images of 
n = 3 individual cell culture experiments.
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A marked reduction of autophagic vesicles in hepatocytes was first observed in 1979 by Pfeifer in rats under-
going PHx38. More recently, autophagy has been established as an essential mechanism required for liver regen-
eration after PHx, since in liver-specific Atg5 knockout mice liver regeneration and cell division are markedly 
impaired after PHx due to reduced ATP levels and decreased β-oxidation39. Here, utilizing a hepatocyte-specific 
Klf6 knockout model, we identified Klf6 as a transcriptional activator of the autophagy related genes Atg7 
and Beclin1 in PHx and acute CCl4 induced liver injury. Metabolism of APAP results in formation of NAPQI 
(N-acetyl-p-benzoquinone imine), which reacts with glutathione (GSH) to form GSH-adducts that can be 
secreted. In APAP overdose with progressive GSH-depletion NAPQI binds to cellular proteins and causes mito-
chondrial damages leading to cell death (mainly necrosis) and inflammation. In liver injury following APAP 
overdose, autophagy represses apoptosis, reduces cellular stress, inflammation and injury by removing damaged 
cells and organelles22–24, 31. Ni et al. showed that SQSTM1/p62 plays an important role in reducing APAP protein 
adducts, while after shRNA-mediated p62-knockdown APAP protein adducts were increased in primary hepato-
cytes23. In aging mice, autophagy and hepatocellular apoptosis are induced, leading to impaired liver regeneration 
following PHx40. In a related study, autophagy played a critical role in liver regeneration and in the preservation 
of cellular quality, preventing hepatocytes from becoming fully senescent and hypertrophic. This effect was most 
likely mediated by p21 and stimulation of interleukins39. Interestingly, in a PHx model, mTOR inhibition severely 
impaired liver regeneration and increased autophagy rate. These effects were partly reversed by stimulation of the 
IL-6 and HGF pathways41.
Our gene array data uncovered altered expression of autophagy-regulatory proteins in mice lacking hepat-
ocyte Klf6 (DeltaKlf6 mice) following PHx. Accordingly, we documented the parallel induction of autophagy 
and KLF6 in several models of liver injury. In DeltaKlf6 mice, autophagy-induction was attenuated compared to 
controls and KLF6-over-expressing HepG2 cells showed increased LC3-II accumulation and formation of auto-
phagosomes, while there was no evidence for increased autophagic flux in conditions of KLF6-over-expression 
as compared to control conditions. We then analyzed whether KLF6 functionally interacts with promoter regions 
of several autophagy-related genes, which contain conserved KLF6-binding motifs. ChIP assay analysis con-
firmed direct binding of KLF6 to promoter regions of ATG7 and BECLIN1. Interestingly, KLF6-mediated tran-
scriptional activation of ATG7 is dependent on p53, since KLF6-overexpression activated the ATG7 promoter in 
HepG2, but not in p53 deficient Hep-G2-303 cells. Conversely, BECLIN1 transcriptional activation was induced 
by KLF6-overexpression under p53 deficient conditions, while KLF6 had no effect on BECLIN1 in HepG2 cells.
A functional interaction between KLF6 and p53 has previously been described. Rubinstein et al. observed 
that a transcriptional effect of KLF6 on the IGF-1 receptor is dependent on the presence of p5327, and KLF6 itself 
is a transcriptional target of IGF1, which also requires p5328. KLF6 can also repress MDM2, which binds to the 
tumor suppressor p53 and thus accelerates its degradation in a mouse model of hepatocellular cancer8. Here, 
we observed a novel transcriptional activity of KLF6 by inducing two autophagy related genes (BECLIN1 in p53 
deficient cells and ATG7 in the presence of p53) is switched, based on the presence or absence of p53. Beyond its 
role in autophagy, Beclin1 has also been described as a tumor suppressor gene in many cancer types and shares a 
BH3 domain with pro-apoptotic genes like Bid or Bad42. In our study expression levels of BAX, BID and BCL-2 
were not changed in KLF6 over-expressing HepG2 cells.
Furthermore, Beclin1 can alter p53 expression by regulating deubiquitination of p53 by USP1043. To date, no 
interaction between KLF6 and either BECLIN1 or ATG7 has been reported. Interestingly, the absence or presence 
of p53 determines a pro-tumorigenic or tumor-suppressing property of autophagy in a mouse model of pancre-
atic cancer44. Thus, KLF6 might serve as an important mediator in autophagy-induction but has no impact on 
apoptosis in the context of acute liver injury.
Taken together, our findings establish that KLF6-expression is induced in models of acute liver injury and 
in patients with ALF. Here, we describe for the first time a direct transcriptional activation of autophagy-related 
genes by KLF6. This transcriptional activation depends on the presence (ATG7) or absence (BECLIN1) of p53. 
Thus, KLF6 drives autophagy-induction and autophagy-related cell death in acute liver injury.
Material and Methods
Cell culture. HepG2 cells were grown in DMEM-High-Glucose medium (Invitrogen, Calrsbad, CA, USA) 
with 10% of fetal bovine serum (FBS, Biochrom, Berlin, Germany, 1000 U/ml penicillin, 0.1 mg/ml streptomycin 
and 2 mM L-glutamine (PAA, Pasching, Austria). Cells were kept in an atmosphere with 5% CO2 under 37 °C fol-
lowing standard protocols. In HepG2-303 cells p53 was stably knocked out and they were cultivated as described 
elsewhere45. Additional cell culture protocols are provided in Supplementary material.
Transfection conditions, reporter assay and BrdU assay. For transient transfection cells were seeded 
one-day prior transfection on different plate formats (6-well, 12-well, 96-well) at a density of 5 × 104 cells/cm2. 
KLF6-over-expressing HepG2 cells were transfected using Transfectine (Bio-Rad, Munich, Germany) at a ratio 
of 3 µl Transfectine per µg DNA as recommended by the manufacturer. KLF6-expression plasmid pcIneo-KLF634 
or empty control vector pcIneo (Promega, Madison, WI, USA) were used at 80 ng per 3.9 cm2 well. For luciferase 
reporter assays HepG2 were co-transfected with pcIneo or pcIneo-KLF6 and 100 ng of reporter plasmid vectors 
pLightSwitch-ATG7, pLightSwitch-BECLIN1 or pLightSwitch-random control plasmid (SwitchGear Genomincs, 
Menlo Park, CA, USA). Luciferase assay was performed using LightSwitch-Luciferase assay system following 
manufacturer’s instruction (SwitchGear Genomics). BrdU assay was performed using the Cell Proliferation 
ELISA BrdU Kit following manufacturer’s instructions (Roche, Mannheim, Germany).
Transmission electron microscopy and Autophagy Tandem Sensor assay. HepG2 cells were 
transfected as described above with pcIneo or pcIneo-KLF6. For induction of autophagy and monitoring of 
autophagosome-formation, HepG2 cells were treated with 15 µM of Rapamycin for 6 h (Medchem Express, 
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Monmouth Junctions, NJ USA). After incubation, cells were fixed for 2 h at room temperature using 2.5% glutar-
aldehyde in 0.1 M PB buffer (0.1 M Na2HPO4; 0.1 M KH2PO4 buffer). Cells were washed with PB buffer, removed 
from the cell culture dish; the cell pellet was postfixed in 2% osmium tetroxide, dehydrated in a graded series of 
alcohol and embedded in epoxy resin. Ultrathin sections were post-stained with uranyl acetate (1%) and lead 
citrate (0.4%). Sections were viewed in a Jeol TEM1400 Plus (Jeol, Tokyo, Japan). For visualization of autopha-
gosomes in pcIneo or pcIneo-KLF6 transfected HepG2 cells we used the Premo™ Autophagy Tandem Sensor 
RFP-GFP-LC3B Kit (Thermo Scientific/Life Technologies, Darmstadt, Germany) according to manufacturer’s 
protocol. Fixed cells were viewed with a Leica SP8 confocal microscope (Leica Microsystems, Wetzlar, Germany).
Chromatin immunoprecipitation assay. For Chromatin immunoprecipitation assay (ChIP) cells were 
cross-linked with a final concentration of 1% formaldehyde for 10 min at 37 °C, then washed and harvested in SDS 
lysis buffer (10% SDS; 0.5 M EDTA; 1 M Tris-HCl; containing proteinase inhibitor cocktail from Sigma-Aldrich, 
St. Louis, MO, USA) and sheared by sonication to fragment DNA. Samples were immunoprecipitated with 10 µg 
of anti-KLF6 antibody (polyclonal antibody KLF6 (R-173) or monoclonal antibody KLF6 (E-10) (Santa Cruz 
Biotechnologies, Dallas, TX, USA), anti-histone H3 antibody (Abcam, Cambridge, UK) or control IgG (Abcam) 
and protein-A/G agarose beads (Santa Cruz Biotechnologies). Following removal of cross-linked DNA/protein 
complexes by Proteinase K (Qiagen, Hilden, Germany) treatment, immunoprecipitated DNA was purified using 
QIAamp DNA Mini Kit (Qiagen) and used for PCR with ATG7 or BECLIN1 primers (Supplementary Table S3), 
encompassing the promoter region −200 bp to −400 bp upstream of transcriptional start site to amplify immu-
noprecipitated DNA, PCR products were visualized on an agarose gel.
Animals and surgical procedures. Mice with a floxed Klf6 targeting vector (C57Bl/6;129Sv, Genentech, 
San Francicso, CA, USA)46 were crossed with mice expressing Cre recombinase (Cre) under control of the albu-
min promoter (B6.Cg-Tg(Alb-cre) 21 Mgn/J; Jackson Labs, Bar Habor, ME, USA). After backcrossing, male off-
spring expressing Cre with two floxed Klf6 alleles were used as the experimental group (‘DeltaKlf6’). Mice with 
two floxed alleles and no Cre expression were used as controls (wt). Temperature, humidity and light-dark cycle 
conditions were controlled; mice were allowed food and water ad libitum. Before surgical intervention animals 
were anesthetized, 70%PHx was performed by removing the left and median lobes of the liver47. Mice were sac-
rificed after 3 h, 12 h, 24 h, 48 h and 72 h following surgical intervention, respectively. Protocol for Affymetrix 
microarray analysis from liver tissue post PHx is given as Supplementary material. To induce APAP-induced 
liver injury C57Bl/6 mice received intraperitoneal injection of APAP (500 mg/kg bodyweight, Sigma-Aldrich) 
and were sacrificed 8 h after APAP-administration26. Carbon tetrachloride (CCl4, Sigma-Aldrich)-induced acute 
liver injury was achieved by intra-peritoneal injection of 2 µl/g bodyweight of CCl4 or corn oil; animals were 
killed after 48 h. Experiments were conducted in three different facilities in accordance with relevant guidelines 
and regulations. Studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Icahn 
School of Medicine at Mount Sinai (reference number LA09-00251), and the State authority for environment and 
animal welfare in Northrhine-Westfalia (LANUV, reference number 84-02.04-2013) for work conducted at the 
University of Duisburg-Essen and the RWTH Aachen. For baseline characteristics see Tables 1 and 2.
Ethical considerations. All investigations in human material and the use of patient samples were approved by the 
Ethics Committee (Institutional Review Board) of the University Hospital Essen (reference numbers: 14-6066-BO 
and 09-4252) and the study protocol conformed to the ethical guidelines of the Declaration of Helsinki. Sample 
allocation in non-acute liver injury patients that underwent bariatric surgery was undertaken following patients’ 
informed consent. As patient data and samples of the historic cohort of ALF patients were analyzed retrospec-
tively from stored samples that were obtained for routine clinical use, informed consent from these subjects was 
explicitly not required according to the local ethics committee.
Histopathology and sample handling. Liver tissue from mice or ALF patients (Supplementary 
Table S13) was stored in 4.5% formalin-solution, paraffin-embedded and sectioned. Stainings were performed 
using standard protocols; rabbit anti-KLF6 (R-173; Santa Cruz Biotechnology). Liver tissue for RNA and protein 
isolation was frozen in liquid nitrogen. Total RNA and protein from liver tissue were isolated by TRIzol® extrac-
tion (Invitrogen), RNA was purified utilizing RNeasy Mini Kit (Qiagen). Protein lysates from cells were prepared 
using lysis buffer (50 mM Tris-HCl; 150 nM NaCl; 0.1% NP-40; 1% desoxycholic acid) containing complete mini 
EDTA-free protease inhibitor cocktail and phosphostop (Roche).
Quantitative real time PCR. Reverse transcription was performed with the QuantiTect-RT kit (Qiagen) 
using 1 µg of total RNA. Specific mRNA expression levels were measured by quantitative realtime-PCR 
(qRT-PCR) performed on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) using QuantiTect SYBR 
Green Kit (Qiagen) in a volume of 15 μl including 2 μl of cDNA. Oligonucleotide sequences of used primers 
are shown in Supplementary Table S4. Melting curves were collected to ascertain specificity of PCR-products. 
Changes in mRNA-expression were calculated by the ΔΔ-Ct method and are presented as foldchange in relation 
to expression of a reference gene (HPRT or Sdha).
Western blotting. For SDS-PAGE 30 µg of total protein were separated; immunoblotting was performed 
using standard procedures with the following primary antibodies: LC3 (Abcam), KLF6-R173 (Santa Cruz 
Biotechnologies), p62 (Enzo Lifesciences, Antwerpen, Belgium), β-Actin 13E5 and GAPDH 14C10 (Cell 
Signaling). After incubation with the appropriate horseradish peroxidase-conjugated secondary antibody, bound 
antibodies were visualized using ECL-Prime (GE Healthcare, Chalfont St. Giles, UK). Blotting images were gen-
erated using ChemiDoc System and Quantity One software (Bio-Rad) to quantify the densities of the bands.
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Statistical analysis. Statistical significance was determined using an unpaired (or paired, when applica-
ble), two-tailed t-test or by one-way ANOVA (with Tukey’s post-hoc test for individual experimental conditions) 
performed with GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). Significance was assumed at 
p ≤ 0.05. If not stated otherwise all data are presented as mean ± SEM.
Data availability. Array data can be found at (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85381), 
under the accession number GSE85381.
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